Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS.
Michael BenatarLanyu ZhangLily WangVolkan GranitJeffrey M StatlandRichard BarohnAndrea SwensonJohn RavitsCarlayne JacksonTed M BurnsJaya TrivediErik P PioroJames B CaressJonathan KatzHengameh ShamsRosa RademakersAndrea MalaspinaLyle W OstrowJoanne Wuunull nullPublished in: Neurology (2020)
Serum NfL may be considered a clinically validated prognostic biomarker for ALS. Serum NfL (and perhaps pNfH), quantified using the Simoa assay, has potential utility as a pharmacodynamic biomarker of treatment effect.